Market capitalization | $1.43b |
Enterprise Value | $1.17b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 11.76 |
EV/Sales (TTM) EV/Sales | 1.97 |
P/S ratio (TTM) P/S ratio | 2.39 |
P/B ratio (TTM) P/B ratio | 1.54 |
Revenue growth (TTM) Revenue growth | -10.64% |
Revenue (TTM) Revenue | $597.40m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
4 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:
4 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:
Dec '23 | |
Current assets | 493 493 |
Fixed assets | 916 916 |
Total Assets | 1,409 1,409 |
Dec '23 | |
Equity | 922 922 |
Debt capital | 487 487 |
Total Capital | 1,409 1,409 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Jack Khattar |
Employees | 652 |
Founded | 2005 |
Website | www.supernus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.